Breast Cancer Now media statements
We respond to the latest census of clinical oncologists from The Royal College of Radiologists
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the latest census of clinical oncologists from The Royal College ...
We respond to announcement from NHS England of a new Innovative Medicines Fund
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the announcement from NHS England of a new Innovative Medicines F...
We respond to a new study into the use of ErSO to shrink oestrogen receptor positive breast cancer in mice
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
Breast Cancer Now welcomes NICE approval of abemaciclib with fulvestrant for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to approve abemaciclib with fulvestrant for ro...
We respond to Macmillan Cancer Support's new research revealing severe nurse shortages are putting cancer patients at risk
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to news of NHS England and Amgen reaching a national agreement to enable early access to Sotorasib for eligible lung cancer patients in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to new data for Enhertu presented at the European Society for Medical Oncology conference
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to a report from the IPPR and CF suggesting it could take over a decade to clear the cancer treatment backlog in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to a new study into eating nuts and breast cancer recurrence
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to Macmillan Cancer Support's warning of 'perfect storm' of Covid and staff shortages
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
We respond to draft NICE decision to not recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today (Tuesday 26 October 2021) announced its provisional decision to not r...
We respond to new research titled “Major global study reveals risk of breast cancer spreading to other parts of the body"
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, responded to new research presented at the Advanced Brea...